收费全文 | 15004篇 |
免费 | 1044篇 |
国内免费 | 75篇 |
耳鼻咽喉 | 78篇 |
儿科学 | 518篇 |
妇产科学 | 455篇 |
基础医学 | 2172篇 |
口腔科学 | 237篇 |
临床医学 | 1438篇 |
内科学 | 3388篇 |
皮肤病学 | 286篇 |
神经病学 | 1501篇 |
特种医学 | 239篇 |
外国民族医学 | 1篇 |
外科学 | 1376篇 |
综合类 | 133篇 |
一般理论 | 12篇 |
预防医学 | 1614篇 |
眼科学 | 343篇 |
药学 | 1072篇 |
中国医学 | 57篇 |
肿瘤学 | 1203篇 |
2023年 | 135篇 |
2022年 | 118篇 |
2021年 | 584篇 |
2020年 | 389篇 |
2019年 | 497篇 |
2018年 | 548篇 |
2017年 | 412篇 |
2016年 | 446篇 |
2015年 | 508篇 |
2014年 | 697篇 |
2013年 | 825篇 |
2012年 | 1383篇 |
2011年 | 1431篇 |
2010年 | 784篇 |
2009年 | 645篇 |
2008年 | 1049篇 |
2007年 | 1081篇 |
2006年 | 973篇 |
2005年 | 908篇 |
2004年 | 738篇 |
2003年 | 656篇 |
2002年 | 615篇 |
2001年 | 73篇 |
2000年 | 32篇 |
1999年 | 55篇 |
1998年 | 100篇 |
1997年 | 59篇 |
1996年 | 36篇 |
1995年 | 48篇 |
1994年 | 40篇 |
1993年 | 33篇 |
1992年 | 18篇 |
1991年 | 19篇 |
1990年 | 16篇 |
1989年 | 15篇 |
1988年 | 9篇 |
1987年 | 19篇 |
1986年 | 10篇 |
1985年 | 8篇 |
1984年 | 12篇 |
1983年 | 10篇 |
1982年 | 17篇 |
1981年 | 12篇 |
1980年 | 7篇 |
1978年 | 9篇 |
1977年 | 8篇 |
1973年 | 4篇 |
1971年 | 3篇 |
1970年 | 3篇 |
1960年 | 3篇 |
Microdeletions encompassing 14q11.2 locus, involving SUPT16H and CHD8, were shown to cause developmental delay, intellectual disability, autism spectrum disorders and macrocephaly. Variations leading to CHD8 haploinsufficiency or loss of function were also shown to lead to a similar phenotype. Recently, a 14q11.2 microduplication syndrome, encompassing CHD8 and SUPT16H, has been described, highlighting the importance of a tight control of at least CHD8 gene-dosage for a normal development. There have been only a few reports of 14q11.2 microduplications. Patients showed variable neurodevelopmental issues of variable severity. Breakpoints of the microduplications were non-recurrent, making interpretation of the CNV and determination of their clinical relevance difficult. Here, we report on two patients with 14q11.2 microduplication encompassing CHD8 and SUPT16H, one of whom had normal intelligence. Review of previous reports describing patients with comparable microduplications allowed for a more precise delineation of the condition and widening of the phenotypic spectrum.
相似文献Areas covered: This review first focuses on the clinical trials evaluating the efficacy and tolerability of nab-paclitaxel in NSCLC at different settings. The approval of nab-paclitaxel in combination with carboplatin at the front-line setting for advanced NSCLC was based on the key phase III study, which showed that nab-paclitaxel/carboplatin was associated with superior overall response rate and favorable toxicity profile compared to sb-paclitaxel/carboplatin. The review also addresses the nab-paclitaxel pharmacology, other combinations (e.g. immunotherapy with PD-1/PD-L1 inhibitors), potential biomarkers (e.g. caveolin-1), and special subgroups (e.g. the elderly, squamous histology).
Expert opinion: Existing data has established the role of nab-paclitaxel in the management of advanced NSCLC. Emerging evidence, such as preliminary results from Keynote-407 and IMpower 131 studies, indicates that novel combinations of nab-paclitaxel/carboplatin and PD-1/PD-L1 inhibitors could further improve clinical benefits with manageable toxicity. Nevertheless, in order to better position nab-paclitaxel and to improve patient selection, future studies are warranted to further understand its mechanism of action, predictive biomarkers, and potential synergism with other agents. 相似文献